Ferrer Announces Distribution Agreement with United Therapeutics for Tyvaso

For Rare Disease Day, Ferrer has strengthened its increasing focus on pulmonary vascular and interstitial lung diseases. The company announced the signing of a distribution agreement with United Therapeutics Corporation for Tyvaso, a treatment for associations with interstitial lung disease. Under the agreement, Ferrer has been appointed to commercialize this treatment to those who need it worldwide and have no other options. The agreement also leverages Ferrer’s strong capabilities and expertise in rare disease and underscores both companies’ commitment to expanding global access to the treatment product. Upon the signing of the agreement, Ferrer made a down-payment to United Therapeutics, who will also receive a transfer price and revenue sharing on future sales of this product. Ferrer is now working with health authorities to determine the appropriate regulatory pathway to obtain approval for Tyvaso in other territories.

Read more about this news release here.